Welcome to our dedicated page for Rockwell Med news (Ticker: RMTI), a resource for investors and traders seeking the latest updates and insights on Rockwell Med stock.
Rockwell Medical, Inc. (Nasdaq: RMTI) is a healthcare company that develops, manufactures, commercializes, and distributes hemodialysis products for dialysis providers worldwide. The Rockwell Medical (RMTI) news feed on Stock Titan focuses on company announcements that relate to its hemodialysis concentrates portfolio, supply agreements with dialysis providers, operational updates, and financial results.
Investors and healthcare observers following RMTI news can expect coverage of product purchase agreements with large dialysis providers, health systems, and specialized care organizations. Recent company communications describe multi-year contracts that include utilization or purchase minimums, options to renew, and supply of liquid and dry acid and bicarbonate concentrates, as well as Rockwell Medical’s dry acid concentrate mix system and bicarbonate cartridge. News items also highlight the company’s efforts to expand its customer base, including adding new dialysis customers in different regions of the United States.
The RMTI news stream also includes quarterly financial and operational results, typically released through earnings press releases and accompanied by conference call details. These updates discuss net sales, gross margin, adjusted EBITDA, and cash position, along with commentary on customer transitions, contract renewals, and manufacturing efficiency. In addition, Rockwell Medical issues news on leadership changes, such as board appointments and executive promotions, and on operational roles related to manufacturing and supply chain management.
Further topics in Rockwell Medical news include participation in industry events, such as exhibiting its hemodialysis concentrates portfolio at professional nephrology conferences, and recognition as a Great Place to Work® and a Fortune Best Workplaces in Manufacturing & Production™ honoree. For users tracking RMTI, this news page provides a centralized view of the company’s corporate developments, financial disclosures, and updates on its hemodialysis products and customer relationships.
Rockwell Medical (Nasdaq: RMTI) will release fourth-quarter and full-year 2025 results on Thursday, March 26, 2026. A press release will be issued at 6:00 AM ET followed by a live webcast at 8:00 AM ET.
Management speakers include Mark Strobeck, Ph.D., president and CEO, and Jesse Neri, SVP and CFO. The webcast will include discussion of financial and operational results followed by a Q&A. Replay will be available at www.RockwellMed.com/Results.
Rockwell Medical (NASDAQ: RMTI) announced it was certified as a Great Place to Work for the fourth consecutive year on February 12, 2026. The company highlighted employee dedication and said the recognition supports its culture focused on quality, reliability and service for dialysis providers and patients.
Rockwell Medical (Nasdaq: RMTI) reported preliminary unaudited results for Q4 and full-year 2025. The company expects Q4 net sales of ~$18.6M and FY 2025 net sales of ~$69.5M. Q4 gross margin is expected to be ~22%, up from 14% in Q3 2025. Management says the company was cash flow positive in Q4 with operating cash flow of ~$2.3M (the second positive quarter in 2025), and expects cash and investments to increase to ~$25M at December 31, 2025. Results are preliminary, unaudited, and subject to year-end close adjustments.
Rockwell Medical (Nasdaq: RMTI) added 30 new customers in the western United States and reports the Western U.S. now accounts for more than 10% of its customer clinic footprint. The company said this expansion generated multi-million dollars in revenue from the new west coast customer base. Rockwell attributes the growth to rapid scaling of production and expanded logistics after meaningful supply-chain disruption for hemodialysis concentrates in the region. New customers include a large integrated non-profit healthcare system, a California chronic kidney disease and dialysis organization, a community acute care hospital, and an innovation-driven renal care center. The company says it can now more efficiently serve existing customers with facilities in the West and is positioned as an alternative supplier across the continental U.S.
Rockwell Medical (Nasdaq: RMTI) announced that its Amended and Restated Product Purchase Agreement with one of the largest U.S. dialysis providers has been extended through December 31, 2026. The extension includes an increase in product pricing for the extended term. The company said the renewal reflects its reliable supply chain and high-quality hemodialysis products and expressed intent to strengthen and potentially expand the strategic partnership beyond 2026. For additional specifics, Rockwell referenced its Form 8-K filed January 5, 2026.
Rockwell Medical (Nasdaq: RMTI) announced on November 18, 2025 that it appointed Joe Dawson to its board of directors and accepted the resignation of Andrea Heslin Smiley, who served five years.
Mr. Dawson brings more than 25 years of experience in renal care and cardiovascular markets, most recently serving as President, North America Division at Nipro Medical Corporation, with strategic P&L, operational oversight, and FDA-regulated market experience relevant to Rockwell's hemodialysis product commercialization and supply-chain goals.
Rockwell Medical (Nasdaq: RMTI) reported third quarter 2025 results on November 12, 2025. Q3 net sales were $15.9M, flat sequentially and down 44% year-over-year after the company's largest customer transitioned to another supplier. The company achieved Adjusted EBITDA of $0.05M in Q3 and reported a net loss of $1.8M for the quarter. Cash, cash equivalents and investments increased to $23.7M at September 30, 2025, up $5.3M from June 30 driven by ATM equity issuances partially offset by the Evoqua asset acquisition.
Rockwell reiterated 2025 guidance: net sales $65.0M–$70.0M, gross margin 16%–18%, and Adjusted EBITDA ($0.5M)–$0.5M. Operating actions included restructuring and new long‑term customer agreements, plus a COO promotion.
Rockwell Medical (Nasdaq: RMTI) announced on November 11, 2025 that Rashad Brown joined as Vice President, Manufacturing and Supply Chain. Brown brings more than two decades of manufacturing and supply chain leadership across Abbott, Fresenius Medical Care, and Hearing Lab Technology, with experience in regulated FDA environments, lean manufacturing, automation to boost overall equipment effectiveness, and supplier negotiation.
The company said Brown will focus on scaling the manufacturing footprint, operational efficiency, reliability for dialysis customers, and supplier performance to support near-term development and long-term growth.
Rockwell Medical (Nasdaq: RMTI) will exhibit its hemodialysis concentrates portfolio at ASN Kidney Week 2025, November 6-9, at the George R. Brown Convention Center in Houston, Booth #316.
On display are liquid and dry acid concentrates (CitraPure, Dri-Sate, RenalPure), bicarbonate concentrates (RenalPure, SteriLyte), a 510(k)-approved single-use bicarbonate cartridge (720g and 900g), the Dry Acid Concentrate Mixer, and accessories including cleaners and salt pellets. The dry products enable on-site mixing with reduced storage, lower cost per treatment, and fewer deliveries. More product details are available on the company website.
Rockwell Medical (Nasdaq: RMTI) announced on October 23, 2025 that it was named to the 2025 Fortune Best Workplaces in Manufacturing & Production list in the small & medium category for the second consecutive year.
The recognition is based on employee feedback about management, colleagues, and company values. Rockwell highlighted an improved ranking year-over-year and quoted Lesley Spriggs, Vice President of Human Resources, praising the company culture built on respect, collaboration, inclusivity, and shared purpose.
The announcement emphasizes employee sentiment and the company’s ongoing focus on workplace culture; no financial data or commercial transactions were disclosed.